866545-96-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1-(5-Bromo-7-azaindole)ethanone is used as a building block for the synthesis of biologically active molecules, contributing to the development of new drugs. Its unique structure and properties make it a promising candidate for creating novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(5-Bromo-7-azaindole)ethanone is utilized as a precursor to new drugs, enabling researchers to explore its potential in the creation of innovative pharmaceutical compounds with improved efficacy and safety profiles.
Used in Drug Discovery Research:
1-(5-Bromo-7-azaindole)ethanone plays a crucial role in drug discovery research, where it is employed to identify and develop new chemical entities with potential therapeutic applications. Its versatility and reactivity in chemical reactions facilitate the exploration of various chemical pathways and mechanisms of action.

Upstream product

• 75-36-5 acetyl chloride 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 875639-40-0 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1-(toluene-4-sulfonyl)-3-[2-(toluene-4-sulfonyl)-2H-pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridine 
• 875639-39-7 5-bromo-1-(toluene-4-sulfonyl)-3-[2-(toluene-4-sulfonyl)-2H-pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridine 
• 1052633-38-1 1-(5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone 
• 1256819-54-1 5-bromo-3-isopropyl-1H-pyrrolo[2,3-b]pyridine 
• 1620574-97-1 5-bromo-3-isopropyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1620574-96-0 2-(5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)propan-2-ol 
• 1071454-96-0 1-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl-1-2(2-trimethylsilanyl-ethoxymethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-ethanone] 

Relevant academic research and scientific papers

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

IMIDAZOPYRIDIN-2-ONE DERIVATIVES

A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.

Discovery of new azaindole-based PI3Kα inhibitors: Apoptotic and antiangiogenic effect on cancer cells

Phosphatidylinositol-3-kinase alpha (PI3Kα) is an important target in cancer due to the deregulation of the PI3K/AKT signaling pathway in many tumors. In this study, we designed [3,5-d]-7-azaindole analogs as PI3Kα inhibitors through the fragment-growing strategy. By varying groups at the 3,5-positions of azaindole, we developed the SAR (Structure-activity relationship) and identified a series of potent PI3Kα inhibitors. Representative azaindole derivatives showed activity in a cellular proliferation and apoptosis assays. Moreover, B3 exhibited strong antiangiogenic effects on cancer cells.

PYRROLO-PYRIDINE KINASE MODULATORS

The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

FUSED RING HETEROCYCLE KINASE MODULATORS

The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

Pyrrolo-pyridine kinase modulators

The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.